NO20074740L - Fremgangsmater for anvendelse av dodsreseptoragonister og EGFR-inhibitorer - Google Patents

Fremgangsmater for anvendelse av dodsreseptoragonister og EGFR-inhibitorer

Info

Publication number
NO20074740L
NO20074740L NO20074740A NO20074740A NO20074740L NO 20074740 L NO20074740 L NO 20074740L NO 20074740 A NO20074740 A NO 20074740A NO 20074740 A NO20074740 A NO 20074740A NO 20074740 L NO20074740 L NO 20074740L
Authority
NO
Norway
Prior art keywords
death receptor
egfr inhibitors
methods
receptor agonists
antibodies
Prior art date
Application number
NO20074740A
Other languages
English (en)
Norwegian (no)
Inventor
Avi J Ashkenazi
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20074740L publication Critical patent/NO20074740L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
NO20074740A 2005-02-18 2007-09-17 Fremgangsmater for anvendelse av dodsreseptoragonister og EGFR-inhibitorer NO20074740L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/061,258 US20060188498A1 (en) 2005-02-18 2005-02-18 Methods of using death receptor agonists and EGFR inhibitors
PCT/US2006/005459 WO2006089015A2 (en) 2005-02-18 2006-02-16 Methods of using death receptor agonists and egfr inhibitors

Publications (1)

Publication Number Publication Date
NO20074740L true NO20074740L (no) 2007-11-14

Family

ID=36912953

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074740A NO20074740L (no) 2005-02-18 2007-09-17 Fremgangsmater for anvendelse av dodsreseptoragonister og EGFR-inhibitorer

Country Status (13)

Country Link
US (1) US20060188498A1 (pt)
EP (1) EP1853300B1 (pt)
JP (2) JP2008532937A (pt)
KR (1) KR20070110852A (pt)
CN (1) CN101180072A (pt)
AU (1) AU2006214292A1 (pt)
BR (1) BRPI0606360A2 (pt)
CA (1) CA2595931A1 (pt)
IL (1) IL184827A0 (pt)
NO (1) NO20074740L (pt)
RU (1) RU2429006C2 (pt)
WO (1) WO2006089015A2 (pt)
ZA (1) ZA200706859B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509201A (pt) * 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
CA2778435A1 (en) * 2008-11-06 2010-05-14 Wayne State University Vaccines targeting cellular death receptors
CA2775350A1 (en) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
EP2569336A1 (en) * 2010-05-14 2013-03-20 Amgen Inc. Enhanced death receptor agonists
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
ITPD20110091A1 (it) * 2011-03-24 2012-09-25 Univ Padova Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico.
WO2012151317A1 (en) * 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
CN102675225A (zh) * 2012-05-16 2012-09-19 浙江理工大学 一种盐酸埃罗替尼的合成方法
RU2580220C2 (ru) * 2012-11-07 2016-04-10 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) РЕКОМБИНАНТНАЯ ПЛАЗМИДА рСрG-СytDA/upp ДЛЯ ЭКСПРЕССИ ГИБРИДНОГО БЕЛКА ЦИТОЗИНДЕЗАМИНАЗА-УРАЦИЛФОСФОРИБОЗИЛ ТРАНСФЕРАЗА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА рСрG-СytDA/upp/VP22 ДЛЯ ЭКСПРЕССИИ ГИБРИДНОГО БЕЛКА ЦИТОЗИНДЕЗАМИНАЗА-УРАЦИЛФОСФОРИБОЗИЛ ТРАНСФЕРЕЗА-VP22, ЛЕЧЕБНАЯ КОМПОЗИЦИЯ ДЛЯ ТЕРАПИИ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ И СПОСОБ ЕЕ ПРИМЕНЕНИЯ
AU2014331049B2 (en) * 2013-10-04 2018-03-29 Torqur Ag Conformationally restricted PI3K and mTOR inhibitors
CN103833853B (zh) * 2013-12-25 2019-05-17 河南大学 新型死亡受体激动性多价抗体及其在制备抗肿瘤药物中的应用
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
NZ725361A (en) * 2014-04-03 2022-09-30 Merck Patent Gmbh Combinations of cancer therapeutics
NO2776305T3 (pt) * 2014-04-23 2018-01-27
UA120108C2 (uk) 2014-12-12 2019-10-10 Мерк Патент Гмбх Комбінація похідної 6-оксо-1,6-дигідропіридазину, що має протиракову активність, з інгібітором рефр
CN105801495A (zh) * 2014-12-31 2016-07-27 徐州万邦金桥制药有限公司 一种盐酸厄洛替尼合成纯化方法
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
CN109195620B (zh) * 2016-04-07 2022-06-28 约翰霍普金斯大学 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
US11369618B2 (en) * 2016-06-17 2022-06-28 The Trustees Of The University Of Pennsylvania Compounds, compositions and methods for prevention and/or treatment of cancer
WO2019154230A1 (zh) * 2018-02-08 2019-08-15 四川大学华西医院 一种包含TRAIL和IgG结合结构域的融合蛋白及其用途
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CN119371319A (zh) * 2024-10-25 2025-01-28 安徽尖峰北卡药业有限公司 一种用于埃罗替尼中间体生产工艺及其生产系统

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
ATE455171T1 (de) 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) * 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
US6391874B1 (en) * 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US7452538B2 (en) * 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
PT981618E (pt) 1997-05-15 2007-11-23 Genentech Inc ''anticorpo anti-apo-2''
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
CN1160338C (zh) * 1998-11-19 2004-08-04 沃尼尔·朗伯公司 N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂
EP2348043A1 (en) * 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
CA2466054C (en) * 2001-11-13 2012-01-03 Genentech, Inc. Apo-2 ligand/trail formulations
RU2240125C2 (ru) * 2002-11-12 2004-11-20 Государственное учреждение Гематологический научный центр РАМН СПОСОБ ЭФФЕКТИВНОЙ ИНДУКЦИИ АПОПТОЗА В СУСПЕНЗИОННЫХ КУЛЬТУРАХ ОПУХОЛЕВЫХ PH$$$ КЛЕТОК КОСТНОГО МОЗГА И ПЕРИФЕРИЧЕСКОЙ КРОВИ БОЛЬНЫХ Ph+ ЛЕЙКОЗАМИ С ПОМОЩЬЮ АНТИСЕНС ОЛИГОНУКЛЕОТИДОВ, СПЕЦИФИЧНЫХ К МРНК ГЕНОВ, ИНГИБИРУЮЩИХ АПОПТОЗ
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US20070066800A1 (en) * 2003-05-09 2007-03-22 Sidhu Sachdev S Apo2l(trail) receptor binding peptides and uses thereof

Also Published As

Publication number Publication date
EP1853300A2 (en) 2007-11-14
IL184827A0 (en) 2008-08-07
ZA200706859B (en) 2008-11-26
WO2006089015A2 (en) 2006-08-24
RU2007134568A (ru) 2009-03-27
EP1853300B1 (en) 2014-07-23
CN101180072A (zh) 2008-05-14
AU2006214292A1 (en) 2006-08-24
BRPI0606360A2 (pt) 2009-06-23
KR20070110852A (ko) 2007-11-20
WO2006089015A3 (en) 2007-08-23
RU2429006C2 (ru) 2011-09-20
JP2012229237A (ja) 2012-11-22
JP2008532937A (ja) 2008-08-21
CA2595931A1 (en) 2006-08-24
US20060188498A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
NO20071789L (no) Fremgangsmate for anvendelse av dodsreseptorligander og CD20-antistoffer
NO20071790L (no) Fremgangsmater for anvendelse av dodsreseptorligander og CD20-antistoffer
WO2006089015A3 (en) Methods of using death receptor agonists and egfr inhibitors
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
EA201001223A1 (ru) Стабилизированные белковые композиции
CL2007001624A1 (es) Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular.
IL258880A (en) Diarylhydantoin compounds
NO20076046L (no) Bindemidler
EA201890278A1 (ru) Антитела к pd-l1
CU24058B1 (es) Antagonistas de pcsk9
CR10147A (es) "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
NO20084546L (no) Diagnostikk og behandlinger for tumorer
GB0724532D0 (en) Trail variants for treating cancer
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
DK2211180T3 (da) Anvendelse af protein SATB2 som markør til at skelne colorectal cancer fra andre former for cancer
DK1885746T3 (da) Sammensætninger relateret til opløselige G-protein-koblede receptorer (sGPCRs)
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
EA201190210A1 (ru) Ингибиторы связывания киназы с белком
GEP20146176B (en) Agonist dr5 binding polypeptides
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
NO20076391L (no) Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin
NO20084795L (no) Fremgangsmate for a behandle, diagnostisere eller detektere kreft
NO20083050L (no) Forbindelser og fremgangsmater for hemming av interaksjon av Bcl-proteiner med bindingspartnere

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application